Inhibition of HSP90 activity leads to the aggregation or proteasomal degradation of these clients, which in turn promotes the disruption of numerous oncogenic signaling pathways essential for tumor cell proliferation and survival [37]. This evidence concerns the gene HSP90AB1 and neoplasm.